Eligible candidates are invited to appear for written test / interviews for the following temporary posts on 10th April 2017 to be conducted at ICMR – NITM, Belagavi
Achillion Pharmaceuticals, Inc announced that the U.S. Patent and Trademark Office (USPTO) has issued the first U.S. Patent to Achillion resulting from its complement factor D research program. U.S. Patent No. 9,598,446 has been granted with claims to compositions of matter for compounds that inhibit complement factor D activity, a key mediator in the complement alternative pathway (AP).

